SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Covid19
Interventions
OTHER

Standard of Care

Patients will receive standard of care for COVID-19.

BIOLOGICAL

SARS-CoV2-CTLS

Patients may receive up to 5 CTL infusions to treat SARA-CoV-2 in combination with standard of care.

Trial Locations (4)

10595

RECRUITING

New York Medical College, Valhalla

19104

NOT_YET_RECRUITING

Children's Hospital of Pennsylvania, Philadelphia

43205

NOT_YET_RECRUITING

Nationwide Children's Hosptial, Columbus

53226

NOT_YET_RECRUITING

Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee

Sponsors
All Listed Sponsors
collaborator

Children's Hospital of Philadelphia

OTHER

collaborator

Medical College of Wisconsin

OTHER

collaborator

Nationwide Children's Hospital

OTHER

lead

New York Medical College

OTHER

NCT04896606 - SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease | Biotech Hunter | Biotech Hunter